Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | IL2 | P60568 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 5/20 | 0.43 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25517797 | 0.90 | GRN (0.49) | ALBIL2F2R | |
| SCHEMBL28951850 | 0.89 | KMT2A (0.55) | CTSLCTSSCTSBMEN1KMT2A | |
| SCHEMBL25533122 | 0.89 | KMT2A (0.55) | CTSLCTSSCTSBMEN1KMT2A | |
| SCHEMBL30174726 | 0.89 | KMT2A (0.55) | CTSLCTSSCTSBMEN1KMT2A | |
| SCHEMBL30174604 | 0.85 | TAS1R3 (0.66) | TAS1R3TAS1R1CTSSCTSKF2R | |
| SCHEMBL28951561 | 0.85 | TAS1R3 (0.66) | TAS1R3TAS1R1CTSSCTSKF2R | |
| SCHEMBL25517407 | 0.85 | TAS1R3 (0.66) | TAS1R3TAS1R1CTSSCTSKF2R | |
| SCHEMBL25232548 | 0.81 | KMT2A (0.58) | ALBIL2CTSLCTSSCTSB | |
| SCHEMBL25232550 | 0.81 | KMT2A (0.58) | ALBIL2CTSLCTSSCTSB | |
| SCHEMBL24113263 | 0.80 | KMT2A (0.54) | CTSLCTSSCTSBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | TAS1R3 4078/4885TAS1R1 3310/4885ALB 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.